Company performance
Current Price
as of Jan 23, 2025$1.88
P/E Ratio
N/A
Market Cap
$394.18M
Description
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Metrics
Overview
- HQSouth San Francisco, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerALLO
- Price$1.88-2.08%
Trading Information
- Market cap$394.18M
- Float68.03%
- Average Daily Volume (1m)2,914,295
- Average Daily Volume (3m)2,745,097
- EPS-$1.56
Company
- Revenue$0.04M
- Rev growth (1yr)-100.00%
- Net income-$66.29M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$57.84M
- EV$386.69M
- EV/Revenue8,992.74
- P/EN/A
- P/S9,145.92
- P/B0.85
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset